Cargando…

Mini-Review: GSDME-Mediated Pyroptosis in Diabetic Nephropathy

Pyroptosis is a recently identified type of lytic programmed cell death, in which pores form in the plasma membrane, and cells swell, rupture, and then release their contents, including inflammatory cytokines. Molecular studies indicated that pyroptosis may occur via a gasdermin D (GSDMD) and caspas...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wen, Sun, Jing, Zhou, Xiaoxi, Lu, Yue, Cui, Wenpeng, Miao, Lining
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637879/
https://www.ncbi.nlm.nih.gov/pubmed/34867412
http://dx.doi.org/10.3389/fphar.2021.780790
_version_ 1784608836415389696
author Li, Wen
Sun, Jing
Zhou, Xiaoxi
Lu, Yue
Cui, Wenpeng
Miao, Lining
author_facet Li, Wen
Sun, Jing
Zhou, Xiaoxi
Lu, Yue
Cui, Wenpeng
Miao, Lining
author_sort Li, Wen
collection PubMed
description Pyroptosis is a recently identified type of lytic programmed cell death, in which pores form in the plasma membrane, and cells swell, rupture, and then release their contents, including inflammatory cytokines. Molecular studies indicated that pyroptosis may occur via a gasdermin D (GSDMD) and caspase-1 (Casp1) -dependent classical pathway, a GSDMD and Casp11/4/5-dependent non-classical pathway, or a gasdermin E (GSDME) and Casp3-dependent pathway. Studies of animal models and humans indicated that pyroptosis can exacerbate several complications of diabetes, including diabetic nephropathy (DN), a serious microvascular complication of diabetes. Many studies investigated the mechanism mediating the renoprotective effect of GSDMD regulation in the kidneys of patients and animal models with diabetes. As a newly discovered regulatory mechanism, GSDME and Casp3-dependent pyroptotic pathway in the progression of DN has also attracted people’s attention. Z-DEVD-FMK, an inhibitor of Casp3, ameliorates albuminuria, improves renal function, and reduces tubulointerstitial fibrosis in diabetic mice, and these effects are associated with the inhibition of GSDME. Studies of HK-2 cells indicated that the molecular and histological features of secondary necrosis were present following glucose stimulation due to GSDME cleavage, such as cell swelling, and release of cellular contents. Therefore, therapies targeting Casp3/GSDME-dependent pyroptosis have potential for treatment of DN. A novel nephroprotective strategy that employs GSDME-derived peptides which are directed against Casp3-induced cell death may be a key breakthrough. This mini-review describes the discovery and history of research in this pyroptosis pathway and reviews the function of proteins in the gasdermin family, with a focus on the role of GSDME-mediated pyroptosis in DN. Many studies have investigated the impact of GSDME-mediated pyroptosis in kidney diseases, and these studies used multiple interventions, in vitro models, and in vivo models. We expect that further research on the function of GDSME in DN may provide valuable insights that may help to improve treatments for this disease.
format Online
Article
Text
id pubmed-8637879
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86378792021-12-03 Mini-Review: GSDME-Mediated Pyroptosis in Diabetic Nephropathy Li, Wen Sun, Jing Zhou, Xiaoxi Lu, Yue Cui, Wenpeng Miao, Lining Front Pharmacol Pharmacology Pyroptosis is a recently identified type of lytic programmed cell death, in which pores form in the plasma membrane, and cells swell, rupture, and then release their contents, including inflammatory cytokines. Molecular studies indicated that pyroptosis may occur via a gasdermin D (GSDMD) and caspase-1 (Casp1) -dependent classical pathway, a GSDMD and Casp11/4/5-dependent non-classical pathway, or a gasdermin E (GSDME) and Casp3-dependent pathway. Studies of animal models and humans indicated that pyroptosis can exacerbate several complications of diabetes, including diabetic nephropathy (DN), a serious microvascular complication of diabetes. Many studies investigated the mechanism mediating the renoprotective effect of GSDMD regulation in the kidneys of patients and animal models with diabetes. As a newly discovered regulatory mechanism, GSDME and Casp3-dependent pyroptotic pathway in the progression of DN has also attracted people’s attention. Z-DEVD-FMK, an inhibitor of Casp3, ameliorates albuminuria, improves renal function, and reduces tubulointerstitial fibrosis in diabetic mice, and these effects are associated with the inhibition of GSDME. Studies of HK-2 cells indicated that the molecular and histological features of secondary necrosis were present following glucose stimulation due to GSDME cleavage, such as cell swelling, and release of cellular contents. Therefore, therapies targeting Casp3/GSDME-dependent pyroptosis have potential for treatment of DN. A novel nephroprotective strategy that employs GSDME-derived peptides which are directed against Casp3-induced cell death may be a key breakthrough. This mini-review describes the discovery and history of research in this pyroptosis pathway and reviews the function of proteins in the gasdermin family, with a focus on the role of GSDME-mediated pyroptosis in DN. Many studies have investigated the impact of GSDME-mediated pyroptosis in kidney diseases, and these studies used multiple interventions, in vitro models, and in vivo models. We expect that further research on the function of GDSME in DN may provide valuable insights that may help to improve treatments for this disease. Frontiers Media S.A. 2021-11-16 /pmc/articles/PMC8637879/ /pubmed/34867412 http://dx.doi.org/10.3389/fphar.2021.780790 Text en Copyright © 2021 Li, Sun, Zhou, Lu, Cui and Miao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Wen
Sun, Jing
Zhou, Xiaoxi
Lu, Yue
Cui, Wenpeng
Miao, Lining
Mini-Review: GSDME-Mediated Pyroptosis in Diabetic Nephropathy
title Mini-Review: GSDME-Mediated Pyroptosis in Diabetic Nephropathy
title_full Mini-Review: GSDME-Mediated Pyroptosis in Diabetic Nephropathy
title_fullStr Mini-Review: GSDME-Mediated Pyroptosis in Diabetic Nephropathy
title_full_unstemmed Mini-Review: GSDME-Mediated Pyroptosis in Diabetic Nephropathy
title_short Mini-Review: GSDME-Mediated Pyroptosis in Diabetic Nephropathy
title_sort mini-review: gsdme-mediated pyroptosis in diabetic nephropathy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637879/
https://www.ncbi.nlm.nih.gov/pubmed/34867412
http://dx.doi.org/10.3389/fphar.2021.780790
work_keys_str_mv AT liwen minireviewgsdmemediatedpyroptosisindiabeticnephropathy
AT sunjing minireviewgsdmemediatedpyroptosisindiabeticnephropathy
AT zhouxiaoxi minireviewgsdmemediatedpyroptosisindiabeticnephropathy
AT luyue minireviewgsdmemediatedpyroptosisindiabeticnephropathy
AT cuiwenpeng minireviewgsdmemediatedpyroptosisindiabeticnephropathy
AT miaolining minireviewgsdmemediatedpyroptosisindiabeticnephropathy